Insulet (NSDQ:PODD) said today that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery devices in Europe with the Glooko+diasend diabetes data management system.
Glooko touted that its data management tech is used at roughly 7,000 provider sites across 23 countries. The Glooko+diasend system allows users to sync and review data from an array of diabetes devices, giving them insights into their insulin regimen.
“Insulet and Glooko are dedicated to bringing innovation to diabetes management around the world. We are delighted to work together to provide Omnipod users across Europe the ability to remotely sync data from their Omnipod Systems using Glooko+diasend,” DJ Cass, GM of Insulet Europe, said in prepared remarks.
“Glooko has a long-standing relationship with Insulet and we are very excited to now expand our collaboration even further within the European markets,” Anders Sonesson, GM of Glooko Europe, added. “We are proud to support the Omnipod System with our universal data management solution and our seamless user experience will appeal to numerous health care providers and their patients throughout Europe, taking clinic workflow, remote patient monitoring and overall diabetes treatment plans to new heights.”
Earlier this year, Insulet assumed direct commercial operations in Europe for its Omnipod insulin pump. The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and selling its Omnipod system in Europe.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.